Ultragenyx Pharmaceutical, Inc. (RARE)
15.43
-0.14
(-0.90%)
USD |
NASDAQ |
Nov 06, 16:00
15.42
-0.01
(-0.06%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Research and Development Expense (Quarterly) : 145.00M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 145.00M |
| June 30, 2026 | 159.00M |
| March 31, 2026 | 179.00M |
| December 31, 2025 | 194.22M |
| September 30, 2025 | 207.61M |
| June 30, 2025 | 156.12M |
| March 31, 2025 | 156.78M |
| December 31, 2024 | 178.69M |
| September 30, 2024 | 161.35M |
| June 30, 2024 | 152.64M |
| March 31, 2024 | 169.64M |
| December 31, 2023 | 160.56M |
| September 30, 2023 | 157.24M |
| June 30, 2023 | 164.95M |
| March 31, 2023 | 161.16M |
| December 31, 2022 | 166.95M |
| September 30, 2022 | 233.30M |
| June 30, 2022 | 150.75M |
| March 31, 2022 | 139.77M |
| December 31, 2021 | 119.48M |
| September 30, 2021 | 110.20M |
| June 30, 2021 | 110.08M |
| March 31, 2021 | 144.15M |
| December 31, 2020 | 117.90M |
| September 30, 2020 | 87.31M |
| Date | Value |
|---|---|
| June 30, 2020 | 80.71M |
| March 31, 2020 | 112.96M |
| December 31, 2019 | 83.06M |
| September 30, 2019 | 100.14M |
| June 30, 2019 | 96.04M |
| March 31, 2019 | 78.10M |
| December 31, 2018 | 71.62M |
| September 30, 2018 | 70.04M |
| June 30, 2018 | 76.84M |
| March 31, 2018 | 75.50M |
| December 31, 2017 | 61.53M |
| September 30, 2017 | 60.41M |
| June 30, 2017 | 58.44M |
| March 31, 2017 | 51.27M |
| December 31, 2016 | 50.75M |
| September 30, 2016 | 48.71M |
| June 30, 2016 | 43.33M |
| March 31, 2016 | 40.42M |
| December 31, 2015 | 44.56M |
| September 30, 2015 | 29.70M |
| June 30, 2015 | 23.10M |
| March 31, 2015 | 17.36M |
| December 31, 2014 | 13.31M |
| September 30, 2014 | 12.85M |
| June 30, 2014 | 11.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 216.41M |
| AbbVie, Inc. | 2.567B |
| Krystal Biotech, Inc. | 13.42M |
| BridgeBio Pharma, Inc. | 143.51M |
| Alnylam Pharmaceuticals, Inc. | 408.54M |